Comparative Pharmacology
Head-to-head clinical analysis: RESPORAL versus VELOSEF.
Peer-Reviewed Evidence
Head-to-head clinical analysis: RESPORAL versus VELOSEF.
RESPORAL vs VELOSEF
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
RESPORAL contains theophylline, a methylxanthine that inhibits phosphodiesterase (PDE) isoenzymes, leading to increased intracellular cAMP and cGMP levels. It also antagonizes adenosine receptors, resulting in bronchodilation and anti-inflammatory effects.
Cephalosporin antibiotic; inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), disrupting peptidoglycan cross-linking.
2 mg orally twice daily
250-500 mg orally every 6 hours or 1-2 g intramuscularly/intravenously every 6-12 hours for moderate to severe infections.
None Documented
None Documented
Terminal half-life is 12 hours (range 10-14 h), supporting twice-daily dosing in most patients.
1-2 hours (normal renal function); prolonged to 10-30 hours in severe renal impairment (CrCl <10 mL/min)
Renal excretion accounts for 70% of elimination (30% unchanged), biliary/fecal 20%, and 10% metabolized.
Primarily renal (80-90% unchanged via glomerular filtration and tubular secretion); small biliary/fecal (5-10%)
Category C
Category C
Cephalosporin Antibiotic
Cephalosporin Antibiotic